Hummingbird Bioscience closes a US$25m extended Series B funding round led by new investor SK Holdings

– SINGAPORE, Singapore –  Hummingbird Bioscience, an innovative biotherapeutics company focused on the discovery and development of new breakthrough therapies, has closed an extended Series B funding round of US$25 million led by new investor SK Holdings bringing the total capital raised through financing activities and strategic partnerships to more than US$65 million to date.…